Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934450 · ClinicalTrials.gov registry record · Phase 1
Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen
A Phase 1 study, sponsored by University of Mississippi, Oxford.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03934450: Completed Phase 1 study, sponsored by University of Mississippi, Oxford.
NCT03934450 is a Phase 1 study that has completed, run by University of Mississippi, Oxford. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03934450, a Phase 1 study, has completed, sponsored by University of Mississippi, Oxford.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.
Primary Outcome
Change in Methemoglobin concentration in blood from baseline (% hemoglobin)
Interventions
- DRUG Placebo
- DRUG RPQ
- DRUG SPQ
- DRUG Primaquine Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-08-17 |
| Est. Completion | 2019-05-01 |
| Phase | Phase 1 |
What the finished NCT03934450 record still lists
NCT03934450 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03934450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03934450 about?
NCT03934450 is a clinical study titled "Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen". To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.
What is the current status of trial NCT03934450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-08-17. Estimated completion is 2019-05-01.
What interventions are being tested in trial NCT03934450?
The interventions under investigation include: Placebo (DRUG), RPQ (DRUG), SPQ (DRUG), Primaquine Phosphate (DRUG).
Who is sponsoring clinical trial NCT03934450?
This trial is sponsored by University of Mississippi, Oxford, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03934450's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI